Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Zoetis (ZTS) , which belongs to the Zacks Medical - Drugs industry, could be a great candidate to consider.This animal health company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 3.78%.For the last reported quarter, Zoetis came out with earn ...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, Feb. 13, 2024. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph will review fourth quarter and full year 2023 financial results and respond to questions from financial analysts during the call. Investors and the public may access the live webcast by visiting the Zoetis website at http://investor.zoetis.com/events-presenta ...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024. Kristin Peck, Chief Executive Officer, will represent the company and respond to questions from analysts. She is scheduled to present at 3:45 p.m. PT. Investors and other interested parties will be able to access a live audio webcast of the presentation by visiting http://investor.zoetis.com/events-presentations. A replay of the presentation will also b ...

Zoetis Inc. (NYSE:ZTS) Q3 2023 Earnings Conference Call November 1, 2023 8:30 AM ET Company Participants Steve Frank - VP of IR Kristin Peck - CEO Wetteny Joseph - CFO Conference Call Participants Jon Block - Stifel Erin Wright - Morgan Stanley Nathan Rich - Goldman Sachs David Westenberg - Piper Sandler Michael Ryskin - Bank of America Brandon Vazquez - William Blair Balaji Prasad - Barclays Chris Schott - J.P. Morgan Operator Welcome to the Third Quarter 2023 Financial Results Conference Call and Webcast ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number:001-35797 Zoetis Inc. (Exact name of registrant as specified in its charter) Delaware 46-0696167 (State or ...

Financial Data and Key Metrics - Revenue for Q2 2023 was $2.2 billion, growing 6% on a reported basis and 9% operationally [15] - Adjusted net income for Q2 2023 was $652 million, growing 15% on a reported basis and 12% operationally [15] - Operational revenue growth was driven by 4% from price and 5% from volume, with volume growth consisting of 2% from in-line products, 2% from new products, and 1% from the dermatology portfolio [15] - Adjusted gross margin improved by 260 basis points to 72.4%, driven by favorable foreign exchange, price increases, and product mix [23] - Capital expenditures in Q2 were $166 million, and the company repurchased $324 million of shares [25] Business Line Performance - Companion animal portfolio grew 11% operationally in Q2, driven by dermatology, osteoarthritis pain, and pet parasiticides [6][16] - Livestock portfolio grew 4% operationally in Q2, driven by poultry, cattle, and fish products [6][17] - Companion animal diagnostics portfolio recorded $92 million in revenue, growing 12% operationally [17] - U.S. companion animal revenue grew 7%, with dermatology products contributing $241 million, growing 10% [18] - International companion animal revenue grew 17% operationally, driven by parasiticides, monoclonal antibodies for osteoarthritis pain, and dermatology products [20][21] Market Performance - U.S. revenue was $1.2 billion, growing 7%, with companion animal products growing 7% and livestock sales growing 5% [18] - International revenue was $1 billion, growing 6% on a reported basis and 11% operationally, with companion animal revenue growing 17% and livestock revenue growing 4% [20] - Strong growth in Europe, particularly in Northern Europe, with double-digit growth in companion animal products [63][64] Company Strategy and Industry Competition - The company is focused on innovation in chronic diseases, dermatology, parasiticides, and monoclonal antibodies for pain [6][12] - Direct-to-consumer campaigns are being used to support growth for products like Librela and Solensia [10] - The company received U.S. regulatory approvals for Librela and Apoquel Chewable in Q2 2023, with Librela expected to launch in the U.S. in November [11] - The company is expanding in large and growing product areas such as parasiticide, dermatology, monoclonal antibodies for pain, vaccines, and diagnostics [12] Management Commentary on Operating Environment and Future Outlook - The company expects full-year operational revenue growth of 6% to 8% and adjusted net income growth of 7% to 9% [9][25] - The company is monitoring macroeconomic conditions, particularly in Asia Pacific, and drought conditions in certain countries [11] - The company remains confident in its ability to deliver on its full-year guidance due to strong underlying demand for animal health products [81] Other Important Information - The company welcomed Ester Banque as EVP and President of U.S. Operations, bringing global healthcare experience [12] - The company published its 2022 sustainability report, highlighting progress in sustainability initiatives [13] - Zoetis was recognized by Fast Company as one of the Best Workplaces for Innovators [14] Q&A Session Summary Question: Impact of NexGard Plus on Simparica Trio - Simparica Trio has a superior label and first-mover advantage, with strong growth expected in Q3 and the second half of 2023 [32] - The company remains confident in competing against NexGard Plus due to the strength of its label and customer relationships [32] Question: Outlook for Companion Animal Growth - Companion animal growth is expected to improve in the second half of 2023, driven by strong demand and easier comparisons in the U.S. [38] - The company expects Q3 to be stronger than Q4 due to easier comps in companion animal and tougher comps in livestock [39] Question: Gross Margin Drivers and Sustainability - Gross margin improvement was driven by favorable foreign exchange, price increases, and product mix, with sustainability expected in the second half of 2023 [42][43] Question: Dermatology Market and Competition - The company expects double-digit growth in dermatology, driven by strong demand for Cytopoint and Apoquel Chewable [50][51] - The company is focused on life cycle innovation in dermatology, including long-acting monoclonal antibodies and new species applications [61][62] Question: EPS Guidance and Pricing Impact - The increase in EPS guidance is primarily due to favorable foreign exchange, with pricing increases typically occurring early in the year [57][58] Question: Global Parasiticide Market Growth - The company expects to grow faster than the global parasiticide market, driven by innovation and increased compliance [71][72][74] Question: U.S. Pet Health Market and Student Loan Repayments - Flat vet visits in the U.S. are due to workforce challenges rather than demand issues, with no significant impact expected from student loan repayments [77][79] Question: Long-Term Growth Commitment - The company remains committed to mid-to-high single-digit revenue growth over the next 3-5 years, driven by innovation and strong market demand [67][68]

Second Quarter 2023 Financial Results Forward-looking Non-GAAP Financial Statements Information This presentation contains forward-looking statements, which reflect the current views of We use non-GAAP*financial measures, such as adjusted net income, adjusted diluted Zoetis with respect to: business plans or prospects; future operating or financial earnings per share, adjusted operating expenses, adjusted gross margin, operational performance, future guidance, future operating models; disruptions in our glo ...

[PART I — FINANCIAL INFORMATION](index=3&type=section&id=PART%20I%20%E2%80%94%20FINANCIAL%20INFORMATION) [Financial Statements](index=3&type=section&id=Item%201.%20Financial%20Statements) The company presents unaudited condensed consolidated financial statements showing revenue growth and a decrease in cash [Condensed Consolidated Statements of Income](index=3&type=section&id=Condensed%20Consolidated%20Statements%20of%20Income) The company reports a 6% quarterly revenue increase to $2.18 billion and a 27% rise in net income to $671 million Q2 & H1 2023 Financial Performance (in millions, except per share data) | Metric | Three Months Ended June 30, 2023 | Three Months Ended June 30, 2022 | % Change | Six Months Ended June 30, 2023 | Six Months Ended June 30, 2022 | % Change | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | **Revenue** | $2,180 | $2,052 | 6.2% | $4,180 | $4,038 | 3.5% | | **Income before taxes** | $872 | $670 | 30.1% | $1,569 | $1,397 | 12.3% | | **Net income attributable to Zoetis** | $671 | $529 | 26.8% | $1,223 | $1,124 | 8.8% | | **Diluted EPS** | $1.45 | $1.12 | 29.5% | $2.64 | $2.38 | 10.9% | | **Dividends declared per share** | $0.375 | $0.325 | 15.4% | $0.750 | $0.650 | 15.4% | [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets decreased to $13.75 billion, primarily due to a significant reduction in cash and cash equivalents Balance Sheet Comparison (in millions) | Account | June 30, 2023 (Unaudited) | December 31, 2022 | | :--- | :--- | :--- | | **Total Current Assets** | $6,183 | $7,506 | | Cash and cash equivalents | $1,717 | $3,581 | | Inventories | $2,701 | $2,345 | | **Total Assets** | **$13,749** | **$14,925** | | **Total Current Liabilities** | $1,769 | $3,167 | | Current portion of long-term debt | $0 | $1,350 | | **Total Liabilities** | **$9,128** | **$10,522** | | **Total Equity** | **$4,621** | **$4,403** | [Condensed Consolidated Statements of Cash Flows](index=8&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Operating cash flow increased while a large debt repayment drove a significant use of cash in financing activities Cash Flow Summary for Six Months Ended June 30 (in millions) | Activity | 2023 | 2022 | | :--- | :--- | :--- | | **Net cash provided by operating activities** | $732 | $645 | | **Net cash used in investing activities** | ($296) | ($321) | | Capital expenditures | ($389) | ($261) | | Proceeds from sale of business | $93 | $0 | | **Net cash used in financing activities** | ($2,296) | ($1,155) | | Principal payments on long-term debt | ($1,350) | $0 | | Purchases of treasury stock | ($607) | ($812) | | **Net decrease in cash and cash equivalents** | **($1,864)** | **($833)** | [Notes to Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes detail strong companion animal product growth, a business sale, debt repayment, and a subsequent acquisition - Revenue from companion animal products grew **9% in Q2 2023 to $1.49 billion**, while livestock revenue was flat at $671 million[24](index=24&type=chunk)[25](index=25&type=chunk) - In Q2 2023, the company sold a majority interest in its pet insurance business, Pumpkin Insurance Services, for net cash proceeds of **$93 million**, recognizing a pre-tax gain of **$101 million**[29](index=29&type=chunk) - On February 1, 2023, the company redeemed in full its **$1.35 billion 3.250% senior notes** due 2023 upon maturity[40](index=40&type=chunk) - Subsequent to the quarter end, on August 3, 2023, Zoetis acquired PetMedix Ltd for upfront cash consideration of approximately **$111 million**[69](index=69&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=25&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses 9% operational revenue growth driven by companion animal products, price increases, and volume gains Q2 2023 Revenue Growth Drivers | Driver | Contribution to Operational Growth | | :--- | :--- | | Price Growth | ~4% | | Volume Growth (Other in-line products) | ~2% | | Volume Growth (New products) | ~2% | | Volume Growth (Key dermatology) | ~1% | | **Total Operational Growth** | **~9%** | - U.S. companion animal revenue growth was driven by the **key dermatology portfolio, Solensia (for OA pain), and small animal vaccines**[99](index=99&type=chunk)[100](index=100&type=chunk) Adjusted Net Income Reconciliation (Q2 2023 vs Q2 2022, in millions) | Description | Q2 2023 | Q2 2022 | | :--- | :--- | :--- | | **GAAP reported net income** | **$671** | **$529** | | Purchase accounting adjustments | $34 | $31 | | Acquisition-related costs | $3 | $1 | | Certain significant items | ($56) | $6 | | **Non-GAAP adjusted net income** | **$652** | **$567** | - Net cash used in financing activities for H1 2023 was **$2.30 billion**, primarily due to the **$1.35 billion repayment of senior notes** and **$607 million in treasury stock purchases**[124](index=124&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=43&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's market risk exposure from foreign exchange and interest rates has not materially changed since year-end 2022 - There have been **no material changes** in the company's market risk exposure related to interest rates and foreign exchange since the year-ended December 31, 2022[135](index=135&type=chunk) [Controls and Procedures](index=43&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective with no material changes to internal controls - As of June 30, 2023, the CEO and CFO concluded that the company's **disclosure controls and procedures are effective**[136](index=136&type=chunk) - **No material changes** to the company's internal control over financial reporting were identified during the most recent fiscal quarter[137](index=137&type=chunk) [PART II — OTHER INFORMATION](index=44&type=section&id=PART%20II%20%E2%80%94%20OTHER%20INFORMATION) [Legal Proceedings](index=44&type=section&id=Item%201.%20Legal%20Proceedings) The company reports ongoing legal matters related to an environmental claim in Brazil and a tax case in the EU - The company is involved in an **environmental proceeding in Ulianopolis, Brazil**, regarding waste disposal, with the matter currently in the environmental assessment phase[60](index=60&type=chunk)[61](index=61&type=chunk) - The company is awaiting a decision from the EU General Court regarding the **Belgium "excess profit" tax scheme** after a hearing on February 15, 2023[62](index=62&type=chunk) [Risk Factors](index=44&type=section&id=Item%201A.%20Risk%20Factors) No material changes to the risk factors disclosed in the 2022 Annual Report on Form 10-K are reported - **No material changes** have occurred to the risk factors disclosed in the company's 2022 Annual Report on Form 10-K[139](index=139&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=44&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company repurchased 1.88 million shares in Q2 2023, with $2.0 billion remaining under its repurchase authorization Share Repurchases for Q2 2023 | Period | Total Shares Purchased (Program) | Average Price Paid Per Share | | :--- | :--- | :--- | | April 2023 | 407,184 | $171.81 | | May 2023 | 759,092 | $176.77 | | June 2023 | 713,942 | $166.32 | | **Total Q2** | **1,880,218** | **$171.73** | - As of June 30, 2023, **$2.0 billion remained** under the company's $3.5 billion share repurchase authorization from December 2021[140](index=140&type=chunk) [Other Information](index=44&type=section&id=Item%205.%20Other%20Information) Two company executives adopted pre-arranged Rule 10b5-1 trading plans for future sales of company stock - In June 2023, executives Roxanne Lagano and Heidi Chen adopted **Rule 10b5-1 trading plans** for the sale of up to 10,807 and 9,905 shares, respectively[143](index=143&type=chunk) [Exhibits](index=45&type=section&id=Item%206.%20Exhibits) This section lists all exhibits filed with the Form 10-Q, including required CEO and CFO certifications - Key exhibits filed include **CEO/CFO certifications under Sarbanes-Oxley** and corporate governance documents[144](index=144&type=chunk)

Financial Data and Key Metrics Changes - The company reported Q1 2023 revenue of $2 billion, growing 1% on a reported basis and 4% operationally, with adjusted net income of $607 million, declining 3% on both a reported and operational basis [14][15][28] - The operational revenue growth of 4% was driven by a 5% increase from price and a 1% decline in volume, primarily due to U.S. companion animal distributor destocking [14][15] - Adjusted gross margins were 70.8%, declining 80 basis points compared to the prior year, attributed to higher manufacturing costs and unfavorable product mix [25][26] Business Line Data and Key Metrics Changes - The livestock portfolio led growth with a 12% operational increase, while companion animal product revenues were flat operationally [6][15] - U.S. livestock sales grew 15%, driven by improved supply of key products, while companion animal products in the U.S. declined 7% [19][23] - International revenue grew 10% operationally, with both companion animal and livestock segments contributing to this growth [23][24] Market Data and Key Metrics Changes - U.S. veterinary clinic visits increased by 2%, with clinic revenue growth of 11% and average spend per visit up 9% [9][20] - Sales out of distributors to clinics were up 8% on a volume basis, and retail sales to pet owners increased by 35% [8][37] - The international livestock segment also grew 10% operationally, driven by cattle and sheep portfolios [25] Company Strategy and Development Direction - The company plans to continue investing in key product areas such as parasiticides, dermatology, monoclonal antibodies, vaccines, and diagnostics to support future growth [11][12] - A new manufacturing site outside Atlanta, Georgia, was purchased to expand capacity for monoclonal antibodies and vaccines, expected to begin operations in 2026 [12] - The company remains committed to delivering strong growth in 2023 based on market leadership and innovative franchises [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year guidance despite economic uncertainties, expecting operational growth of 6% to 8% in revenue and 7% to 9% in adjusted net income [5][29] - The company anticipates a return to growth in U.S. diagnostics and expects strong demand for innovative companion animal products [10][11] - Management noted that the first quarter results were in line with expectations and emphasized the importance of a diverse portfolio for steady growth [14][29] Other Important Information - Capital expenditures in Q1 were $223 million, with expectations for a significant increase throughout 2023 [28] - The company repurchased $283 million of shares and increased dividends by over 15% compared to Q1 2022 [28] Q&A Session Summary Question: Is the channel now normalized in the U.S.? - Management confirmed that the channel is at normalized levels and discussed the destocking dynamics that occurred in Q1, which were anticipated [32][35] Question: Was there a stocking benefit across livestock in the segment in the quarter? - Management indicated that livestock growth was driven by resupply and increased supply of key products, but expects flat growth for the year [39][40] Question: What drove the decline in the dermatology segment? - The decline was attributed to destocking from pre-price buy-ins and promotional impacts, but management expects double-digit growth for the rest of the year [41][68] Question: Any feedback from the price increases at the beginning of the year? - Management reported no pushback from veterinarians or pet owners regarding price increases, with significant growth observed in distributor sales to clinics and retail sales to pet owners [70][73]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number:001-35797 Zoetis Inc. (Exact name of registrant as specified in its charter) Delaware 46-0696167 (State or oth ...